CAY10594

SKU: orb1299954

Description

CAY10594 is a potent and selective phospholipase D2 (PLD2) inhibitor. It has been shown to protect against acetaminophen-induced hepatotoxicity in vivo by modulating the p-GSK-3β/JNK signaling pathway, making it a valuable research tool for studying liver injury and PLD2-related cellular processes.

Research Area

Cardiovascular Research, Cell Biology, Immunology & Inflammation, Metabolism Research, Pharmacology & Drug Discovery, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1130067-34-3
• MW: 428.53
• Purity: 98.00% (May vary between batches)
• Formula: C₂₆H₂₈N₄O₂
• SMILES: O=C(NCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc2ccccc2c1
• Target: Interleukin,GSK-3,GRK,ALK,Dehydrogenase,Apoptosis,Phospholipase,CXCR,STAT
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.33 mM);DMSO:20 mg/mL (46.67 mM)

Bioactivity

• In Vivo:
  CAY10594 administration markedly blocked the acute liver injury in a dose-dependent manner, showing almost complete inhibition with 8 mg/kg of CAY10594. During the pathological progress of acute liver injury, GSH levels are decreased, and this is significantly recovered upon the administration of CAY10594 at 6 hours post APAP challenge. GSK-3β (Serine 9)/JNK phosphorylation is mainly involved in APAP-induced liver injury. CAY10594 administration strongly blocked GSK-3β (Serine 9)/JNK phosphorylation in the APAP-induced acute liver injury model. Consistently, sustained JNK activation in the cytosol and mitochondria from hepatocytes were also decreased in CAY10594-treated mice. Many types of immune cells are also implicated in APAP-induced liver injury. However, neutrophil and monocyte populations were not different between vehicle- and CAY10594-administered mice which are challenged with APAP. Therapeutic administration of CAY10594 also significantly attenuated liver damage caused by the APAP challenge, eliciting an enhanced survival rate.
  Read more...
• Animal Research:
  Mice were fasted for 16 hours before APAP injection. APAP (500 mg/kg) was administered with oral gavage in mice. CAY10594 (N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalene carboxamide)23 was dissolved in 1% DMSO and intraperitoneally administered to mice 30 minutes prior to APAP injection for examining protective effects or after 3 hours from APAP challenge for investigating therapeutic effects of CAY10594.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Phospholipase, Inhibitor, inhibit, PLD2, CAY10594, CAY-10594, CAY 10594

Compound Identifiers

PubChem CID

25105715